Treatment progress of primary light-chain amyloidosis
10.3760/cma.j.cn115356-20201211-00301
- VernacularTitle:原发性轻链型淀粉样变的治疗进展
- Author:
Yanying YU
;
Jian LI
- From:
Journal of Leukemia & Lymphoma
2021;30(1):11-13
- CountryChina
- Language:Chinese
-
Abstract:
Primary light-chain (AL) amyloidosis is a rare, fatal and clonal plasma cell dyscrasia. The bortezomib-based treatment has improved the survival of AL amyloidosis patients, but the prognosis of advanced patients is still poor. More effective novel agents are urgently needed. At the 62nd American Society of Hematology (ASH) Annual Meeting, the clinical data of a variety of new drugs (such as anti-CD38 monoclonal antibody, bcl-2 inhibitor combined with statins and CAEL-101, etc.) were reported.
